Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4
4 · Zenas BioPharma, Inc. · Filed Sep 18, 2024
Insider Transaction Report
Form 4
Transactions
- Conversion
Series C Convertible Preferred Stock
2024-09-16−1,742,858→ 0 total→ Common Stock (200,718 underlying) - Conversion
Common Stock
2024-09-16+180,635→ 180,635 total - Conversion
Common Stock
2024-09-16+200,718→ 801,624 total - Conversion
Common Stock
2024-09-16+420,271→ 600,906 total - Conversion
Series A Convertible Preferred Stock
2024-09-16−1,568,480→ 0 total→ Common Stock (180,635 underlying) - Conversion
Series B Convertible Preferred Stock
2024-09-16−3,649,263→ 0 total→ Common Stock (420,271 underlying)
Footnotes (3)
- [F1]On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F3]On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.